← All trials
NCT05500482
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 15, 2022
- Primary completion
- Jun 30, 2025
- Completion date
- Dec 31, 2025
- First posted
- Aug 15, 2022
- Last posted
- Aug 16, 2022
- Enrollment
- 72000
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Christian Medical College, Vellore, IndiaLead sponsor
- University of LondonCollaborator
- Bill and Melinda Gates FoundationCollaborator
- Christian Medical College, Vellore, IndiaOverall official - principal investigator
- Christian Medical College, Vellore, IndiaReponsible party - principal investigator
- Christian Medical College, Vellore, IndiaStudy chair
- Imperial College LondonCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.